We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time
News

AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time

AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time
News

AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AiCuris announced that the last subject has completed their Phase-II trial "A double-blind randomized placebo controlled dose-finding trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection".

The trial has been completed two months earlier than planned. Indeed, in the later stages of the trial, enrollment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.

“We were surprised by the interest in our trial and the number of requests for participation that we received from people infected with herpes simplex virus” said Dr. Burkhard Timmler, Associate Director Clinical Development at AiCuris. “In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes”.

AiCuris plans to have the first data available in early 2011. “We hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes. Our ultimate goal is to address the still existing unmet medical need in the field of genital herpes infections with this drug which acts by a unique mode of action”, adds Prof. Rübsamen-Schaeff, CEO of AiCuris.
Advertisement